Abstract: The prevalence and incidence rates of kidney stone disease (KSD) in Taiwan are high; however, the association between lipid profile and KSD has yet to be investigated. The aim of this longitudinal study was to investigate the association between lipid profile with baseline and incident KSD in a large Taiwanese cohort. A total of 27,002 people enrolled in the Taiwan Biobank (TWB) were followed for a median of 4 years and classified into two groups according to whether they had (n = 1813; 6.7%) or did not have (n = 25,189; 93.3%) KSD at baseline. The presence of KSD was defined according to a self-reported history of kidney stones. The participants with baseline KSD (n = 1813) were excluded from the follow-up study, and the remaining participants were classified into two groups consisting of those who had (n = 640; 2.5%) or did not have (n = 24,549; 97.5%) incident KSD.

After multivariable analysis, compared to quartile 1 of lipid profile, the participants in quartile 4 of triglycerides, quartiles 3 and 4 of high-density lipoprotein cholesterol (HDL-C), and quartile 4 of total cholesterol (Chol)/HDL-C ratio were significantly associated with baseline KSD. In the follow-up study, the participants in quartiles 2, 3, and 4 of triglycerides; quartile 2 of Chol; quartile 4 of HDL-C; quartile 3 of LDL-C; and quartiles 3 and 4 of Chol/HDL-C ratio were significantly associated with incident KSD. Our results showed that hypertriglyceridemia (67–93 mg/dL) was associated with a 1.463-fold increased risk of incident KSD and that low HDL-C (>63 mg/dL) protected against incident KSD formation. In addition, a Chol/HDL-C ratio larger than 3.64 was associated with a 1.381-fold increased risk of incident KSD. Our findings may imply that the optimal management of dyslipidemia may be associated with a lower risk of developing kidney stones.

Keywords: kidney stone disease; lipid profile; follow-up; Taiwan Biobank
1. Introduction

Kidney stone disease (KSD) is an increasing healthcare problem in Taiwan and worldwide [1]. In Taiwan, the overall age-adjusted prevalence rates of KSD are approximately 9%, 6%, and 7% in males, females, and all subjects, respectively [2]. KSD often recurs, with relapse rates of 50% in 5–10 years and 75% in 20 years [3]. The etiology of KSD is multifactorial and is associated with genetic predisposition, dietary habits, climate change, recurrent urinary infections, anatomical abnormalities, and medical conditions [4]. Among the medical conditions, metabolic syndrome has been associated with an increased risk of KSD [5–10]. Moreover, each component of metabolic syndrome including elevated body mass index (BMI) [9], dyslipidemia [11–15], diabetes [16,17], and hypertension [18,19] has also been associated with an increased risk of KSD. The complications of KSD include urinary obstruction, hydronephrosis, and pyelonephritis, which can lead to urosepsis, the leading cause of KSD-related mortality [20,21]. KSD is also associated with many comorbidities and increased risks of metabolic bone disease, chronic kidney disease, and cardiovascular events [22]. Hence, determining the risk factors for KSD is vital so that clinicians can optimally manage patients and prevent these complications.

Dyslipidemia is a common disorder globally. In Taiwan, the mean prevalence rates of hypertriglyceridemia and hypercholesterolemia are 29.26% and 43.96%, respectively, which are similar to the United States [23,24]. Dyslipidemia is a well-established risk factor for cardiovascular diseases, including cerebrovascular accident and coronary heart disease [25,26]. A study regarding the association between dyslipidemia and KSD reported a higher prevalence of dyslipidemia in patients with stone formation compared to those without stones [11]. Another study suggested a weak association [27], whereas another study did not find any association [9]. Two retrospective analyses investigated the efficacy of statin therapy to prevent KSD, and found that these lipid-lowering agents decreased the risk of developing KSD [28,29]. Despite the discrepancies in the trends of lipid profiles between different studies, their results raise the possibility of another modifiable factor to prevent KSD.

Nevertheless, these previous studies have reported inconsistent findings, the sample sizes have been limited, and there have been differences in the study population and design. Moreover, the association between lipid profile and KSD has not be examined in a large cohort follow-up study. Therefore, the aim of this longitudinal study was to investigate the association between lipid profile, including Chol/HDL-C ratio, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (Chol) with baseline and incident KSD in around 27,000 participants enrolled in the largest biobank in Taiwan.

2. Materials and Methods

2.1. Ethics Statement

The Institutional Review Board (IRB) of Kaohsiung Medical University Hospital approved this study (KMUHIRB-E(I)-20210058). The Ethics and Governance Council and the IRB of Biomedical Science Research, Academia Sinica, Taiwan, gave ethical approval for the Taiwan Biobank (TWB). All participants signed written informed consent before participating in the study, which followed the Declaration of Helsinki.

2.2. TWB

The TWB is the largest biobank in Taiwan, and it consists of genomic and lifestyle data of Taiwanese residents [30,31]. The participants in the TWB are enrolled from the community, with the inclusion criteria being: (1) age 30–70 years and (2) no cancer history. After providing written informed consent, the participants provided blood samples and underwent a physical examination. All of the participants also underwent a face-to-face interview with a TWB researcher, during which they completed a questionnaire asking about dietary habits, family medical history, personal medical history, and lifestyle factors.
2.3. Demographic, Laboratory, and Medical Data

Baseline data including demographics (sex and age), smoking and alcohol history, laboratory data (uric acid, LDL-C, HDL-C, triglycerides, Chol, albumin, and fasting glucose), and medical history (hypertension and diabetes mellitus [DM]) were recorded. Estimated glomerular filtration rate (eGFR) was estimated using the 4-variable Modification of Diet in Renal Disease study equation [32].

2.4. Presence of KSD

The participants were asked in a standardized interview whether they had ever had KSD. They were then asked again during follow-up interviews.

2.5. Study Participants

Overall, 27,002 participants who were followed for a median period of 4 years and had complete follow-up data were enrolled. The association between lipid profile and KSD prevalence was first evaluated in the whole cross-sectional cohort (n = 27,002). Participants with a KSD history (n = 1813) were then excluded from analysis of the longitudinal cohort. Finally, we examined the association between lipid profile and incident KSD in the participants without baseline KSD (n = 25,189) (Figure 1).

![Figure 1. Flowchart of study population.](image)

2.6. Statistical Analysis

All statistical analyses were performed using SPSS version 20.0 for Windows (SPSS Inc., Chicago, IL, USA). Data are presented as percentages or means ± standard deviations. Differences in categorical variables were analyzed using the chi-square test, and differences in continuous variables were analyzed using independent t-tests. Associations between lipid profile quartiles with baseline and incident KSD were examined using logistic regression analysis. The quartile cutoff values were: ≤66, 67–93, 94–136 and >137 mg/dL for triglycerides; ≤171, 172–193, 194–217 and >218 mg/dL for Chol; ≤45, 46–63, 54–62 and >63 mg/dL for HDL-C; ≤100, 101–120, 121–141 and >142 mg/dL for LDL-C; and ≤3.02, 3.02–3.63, 3.64–4.38 and >4.39 for Chol/HDL-C ratio. Quartiles 1 of Chol/HDL-C, Chol, triglycerides, LDL-C, and HDL-C were used as reference categories according to the lowest incidence rate. Significant variables in univariable analysis were entered into
multivariable analysis. A *p* value of less than 0.05 was considered to indicate a statistically significant difference.

### 3. Results

The mean age of the 27,002 participants (9552 males and 17,450 females) was 51.2 ± 10.4 years. The participants were stratified into two groups according to baseline KSD (−) (*n* = 25,189; 93.3%) or KSD (+) (*n* = 1813; 6.7%).

#### 3.1. Comparison of Clinical Characteristics among Participants According to Baseline KSD

A comparison of the clinical characteristics among the two groups is shown in Table 1. Compared to the participants without baseline KSD, those with baseline KSD were older and male predominant and had higher smoking and alcohol history, higher prevalence of DM and hypertension, higher fasting glucose, higher albumin, higher triglyceride, lower HDL-C, higher Chol/HDL-C ratio, and lower eGFR. However, total cholesterol and LDL-C levels were not significantly different between the two groups.

### Table 1. Comparison of clinical characteristics among participants according to baseline kidney stone disease in all study participants (*n* = 27,002).

| Characteristics              | Baseline Kidney Stone (−) (*n* = 25,189) | Baseline Kidney Stone (+) (*n* = 1813) | *p*  |
|------------------------------|-----------------------------------------|---------------------------------------|------|
| Age (year)                   | 51.0 ± 10.4                             | 54.1 ± 9.2                            | <0.001|
| Male gender (%)              | 33.6                                    | 59.6                                  | <0.001|
| Smoking history (%)          | 23.2                                    | 39.1                                  | <0.001|
| Alcohol history (%)          | 8.2                                     | 11.8                                  | <0.001|
| DM (%)                       | 5.0                                     | 9.4                                   | <0.001|
| Hypertension (%)             | 12.1                                    | 25.5                                  | <0.001|
| Laboratory parameters        |                                         |                                       |      |
| Fasting glucose (mg/dL)      | 95.9 ± 20.0                             | 100.3 ± 24.6                          | <0.001|
| Albumin (g/dL)               | 4.55 ± 0.23                             | 4.57 ± 0.23                           | <0.001|
| Triglyceride (mg/dL)         | 112.9 ± 82.5                            | 129.6 ± 90.4                          | <0.001|
| Total cholesterol (mg/dL)    | 195.5 ± 35.4                            | 194.3 ± 35.5                          | 0.150 |
| HDL-C (mg/dL)                | 54.5 ± 13.2                             | 50.6 ± 12.9                           | <0.001|
| LDL-C (mg/dL)                | 121.6 ± 31.6                            | 124.4 ± 32.0                          | 0.307 |
| Chol/HDL-C ratio             | 3.76 ± 1.02                             | 4.03 ± 1.08                           | <0.001|
| eGFR (mL/min/1.73 m²)        | 103.2 ± 23.8                            | 96.3 ± 24.3                           | <0.001|

Abbreviations. DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Chol/HDL-C, the ratio of total cholesterol to HDL-C; eGFR, estimated glomerular filtration rate.

#### 3.2. Associations among Lipid Profile Quartiles with Baseline KSD

Table 2 shows the association of quartile of lipid profile and baseline KSD using multivariable linear regression analysis in all study participants (*n* = 27,002). After adjusting for age, sex, smoking and alcohol history, diabetes, hypertension, fasting glucose, albumin, and eGFR (significant variables of Table 1), the participants in quartile 4 of triglyceride (vs. quartile 1; odds ratio [OR], 1.269; 95% confidence interval [CI], 1.095 to 1.470; *p* = 0.002), quartile 3 of HDL-C (vs. quartile 1; OR, 0.844; 95% CI, 0.732 to 0.972; *p* = 0.019), quartile 4 of HDL-C (vs. quartile 1; OR, 0.809; 95% CI, 0.694 to 0.943; *p* = 0.003), and quartile 4 of Chol/HDL-C ratio (vs. quartile 1; OR, 1.207; 95% CI, 1.041 to 1.400; *p* = 0.013) were significantly associated with baseline KSD.
Table 2. Association of quartile of lipid profile and baseline kidney stone disease using logistic regression analysis in all study participants (n = 27,002).

| Quartile of Lipid Profile | Univariable (Baseline Kidney Stone) | Multivariable (Baseline Kidney Stone) |
|---------------------------|-------------------------------------|---------------------------------------|
|                           | Odds Ratio (95% CI)                  | p                                     |
|                           |                                     | Odds Ratio (95% CI)                  | p                                     |
| Triglyceride              | Reference                            | Reference                             | Reference                             |
| Quartile 1                | Reference                            | Reference                             | Reference                             |
| Quartile 2                | 1.328 (1.145–1.540)                 | <0.001                                | 1.097 (0.943–1.276)                  | 0.229                                |
| Quartile 3                | 1.416 (1.223–1.639)                 | <0.001                                | 1.030 (0.885–1.198)                  | 0.702                                |
| Quartile 4                | 1.333 (1.275–1.393)                 | <0.001                                | 1.269 (1.095–1.470)                  | 0.002                                |
| Total cholesterol         | Reference                            | Reference                             | Reference                             |
| Quartile 1                | Reference                            | Reference                             | Reference                             |
| Quartile 2                | 0.912 (0.798–1.041)                 | 0.173                                 | 0.944 (0.823–1.082)                  | 0.407                                |
| Quartile 3                | 0.885 (0.774–1.011)                 | 0.072                                 | 0.917 (0.798–1.053)                  | 0.220                                |
| Quartile 4                | 0.936 (0.819–1.069)                 | 0.328                                 | 1.004 (0.872–1.155)                  | 0.956                                |
| HDL-C                     | Reference                            | Reference                             | Reference                             |
| Quartile 1                | Reference                            | Reference                             | Reference                             |
| Quartile 2                | 0.741 (0.6570.837)                  | <0.001                                | 0.961 (0.848–1.089)                  | 0.532                                |
| Quartile 3                | 0.549 (0.480–0.627)                 | <0.001                                | 0.844 (0.732–0.972)                  | 0.019                                |
| Quartile 4                | 0.452 (0.393–0.521)                 | <0.001                                | 0.809 (0.694–0.943)                  | 0.005                                |
| LDL-C                     | Reference                            | Reference                             | Reference                             |
| Quartile 1                | Reference                            | Reference                             | Reference                             |
| Quartile 2                | 0.955 (0.833–1.094)                 | 0.507                                 | 0.948 (0.825–1.090)                  | 0.456                                |
| Quartile 3                | 1.035 (0.904–1.183)                 | 0.621                                 | 1.006 (0.876–1.155)                  | 0.929                                |
| Quartile 4                | 1.083 (0.948–1.236)                 | 0.242                                 | 1.045 (0.911–1.200)                  | 0.529                                |
| Chol/HDL-C ratio          | Reference                            | Reference                             | Reference                             |
| Quartile 1                | Reference                            | Reference                             | Reference                             |
| Quartile 2                | 1.228 (1.055–1.429)                 | 0.008                                 | 1.018 (0.873–1.189)                  | 0.816                                |
| Quartile 3                | 1.563 (1.352–1.807)                 | <0.001                                | 1.099 (0.946–1.277)                  | 0.218                                |
| Quartile 4                | 2.012 (1.750–2.313)                 | <0.001                                | 1.207 (1.041–1.400)                  | 0.013                                |

Values expressed as odds ratio and 95% confidence interval (CI). Adjusted for age, sex, smoking and alcohol history, diabetes, hypertension, fasting glucose, albumin, and eGFR (significant variables of Table 1). The cutoff values of quartiles were ≤66, 67–93, 94–136 and >137 mg/dL of triglyceride; ≤171, 172–193, 194–217 and >218 mg/dL of total cholesterol; ≤45, 46–63, 64–62 and >63 mg/dL of HDL-C; ≤100, 101–120, 121–141 and >142 mg/dL of LDL-C; and ≤3.02, 3.02–3.63, 3.64–4.38 and >4.39 of Chol/HDL-C ratio. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Chol/HDL-C, the ratio of total cholesterol to HDL-C.

Figure 2A–E illustrates the adjusted curves of baseline KSD among the quartiles of lipid profile.

Figure 2. The adjusted curves of baseline kidney stone disease among the quartiles of triglyceride (A), total cholesterol (B), HDL-C (C), LDL-C (D), and Chol/HDL-C (E). HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Chol/HDL-C, the ratio of total cholesterol to HDL-C. Dashed lines mean odds ratio. Solid lines mean 95% confidence interval.
After exclusion the participants with a history of KSD ($n = 1813$), the mean age of study population in the follow-up study (8471 males and 16,718 females) was $51.0 \pm 10.4$ years. The participants were stratified into two groups according to incident KSD ($-$) ($n = 24,549$; 97.5%) or KSD ($+$) ($n = 640$; 2.5%).

### 3.3. Comparison of Clinical Characteristics among Participants According to Incident KSD

A comparison of the clinical characteristics among the two groups is shown in Table 3. Compared to the participants without incident KSD, those with incident KSD were older and male predominant and had higher smoking and alcohol history, higher prevalence of hypertension, higher fasting glucose, higher albumin, higher triglyceride, lower HDL-C, higher LDL-C, higher Chol/HDL-C ratio, and lower eGFR. However, total cholesterol was not significantly different between the two groups.

### Table 3. Comparison of clinical characteristics among participants according to incident kidney stone disease in study participants without baseline kidney stone disease ($n = 25,189$).

| Characteristics           | Incident Kidney Stone ($-$) ($n = 24,549$) | Incident Kidney Stone ($+$) ($n = 640$) | $p$  |
|---------------------------|--------------------------------------------|----------------------------------------|------|
| Age (year)                | $51.0 \pm 10.4$                            | $52.1 \pm 9.8$                         | 0.005|
| Male gender (%)           | $33.1$                                     | $55.6$                                 | $<0.001$|
| Smoking history (%)       | $22.9$                                     | $37.3$                                 | $<0.001$|
| Alcohol history (%)       | $8.0$                                      | $13.0$                                 | $<0.001$|
| DM (%)                    | $4.9$                                      | $6.4$                                  | 0.093|
| Hypertension (%)          | $12.0$                                     | $18.4$                                 | $<0.001$|
| Laboratory parameters     |                                            |                                        |      |
| Fasting glucose (mg/dL)   | $95.9 \pm 19.9$                            | $98.3 \pm 20.5$                        | 0.002|
| Albumin (g/dL)            | $4.55 \pm 0.23$                            | $4.58 \pm 0.24$                        | 0.002|
| Triglyceride (mg/dL)      | $112.4 \pm 81.5$                           | $130.7 \pm 111.7$                     | $<0.001$|
| Total cholesterol (mg/dL) | $195.5 \pm 35.5$                           | $196.7 \pm 33.4$                      | 0.407|
| HDL-C (mg/dL)             | $54.6 \pm 13.2$                            | $21.3 \pm 13.2$                       | $<0.001$|
| LDL-C (mg/dL)             | $121.5 \pm 31.6$                           | $124.6 \pm 31.4$                      | 0.013|
| Chol/HDL-C ratio          | $3.75 \pm 1.02$                            | $4.01 \pm 1.03$                       | $<0.001$|
| eGFR (mL/min/1.73 m$^2$)  | $103.3 \pm 23.8$                           | $99.2 \pm 23.9$                       | $<0.001$|

Abbreviations. DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Chol/HDL-C, the ratio of total cholesterol to HDL-C; eGFR, estimated glomerular filtration rate.

### 3.4. Associations among Lipid Profile Quartiles with Incident KSD

Table 4 shows the association of quartile of lipid profile and incident KSD using multivariable linear regression analysis in all study participants ($n = 25,189$). After adjusting for age, sex, smoking and alcohol history, hypertension, fasting glucose, albumin, and eGFR (significant variables of Table 3), the participants in quartile 2 of triglyceride (vs. quartile 1; OR, 1.463; 95% CI, 1.138 to 1.881; $p = 0.003$), quartile 3 of triglyceride (vs. quartile 1; OR, 1.458; 95% CI, 1.134 to 1.875; $p = 0.003$), quartile 4 of triglyceride (vs. quartile 1; OR, 1.532; 95% CI, 1.190 to 1.972; $p = 0.001$), quartile 2 of total cholesterol (vs. quartile 1; OR, 1.322; 95% CI, 1.059 to 1.651; $p = 0.014$), quartile 4 of HDL-C (vs. quartile 1; OR, 0.772; 95% CI, 0.600 to 0.993; $p = 0.044$), quartile 3 of LDL-C (vs. quartile 1; OR, 1.390; 95% CI, 1.108 to 1.743; $p = 0.004$), quartile 3 of Chol/HDL-C ratio (vs. quartile 1; OR, 1.381; 95% CI, 1.082 to 1.763; $p = 0.010$), and quartile 4 of Chol/HDL-C ratio (vs. quartile 1; OR, 1.403; 95% CI, 1.097 to 1.793; $p = 0.007$) were significantly associated with incident KSD.
### Table 4. Association of quartile of lipid profile and incident kidney stone disease using logistic regression analysis in study participants without baseline kidney stone disease ($n = 25,189$).

| Quartile of Lipid Profile | Univariable (Incident Kidney Stone) | Multivariable (Incident Kidney Stone) |
|---------------------------|-------------------------------------|---------------------------------------|
|                           | Odds Ratio (95% CI)                  | $p$                                   | Odds Ratio (95% CI) | $p$       |
| **Triglyceride**          |                                     |                                       |                      |           |
| Quartile 1                | Reference                           | Reference                             | 1.463 (1.138–1.881) | 0.003     |
| Quartile 2                | 1.636 (1.275–2.098)                 | <0.001                                | 1.458 (1.134–1.875) | 0.003     |
| Quartile 3                | 1.765 (1.380–2.257)                 | <0.001                                | 1.532 (1.190–1.972) | 0.011     |
| Quartile 4                | 2.091 (1.644–2.660)                 | <0.001                                |                      |           |
| Total cholesterol         |                                     |                                       |                      |           |
| Quartile 1                | Reference                           | Reference                             | 1.119 (0.883–1.417) | 0.353     |
| Quartile 2                | 1.083 (0.863–1.360)                 | 0.491                                 | 1.113 (0.885–1.399) | 0.361     |
| Quartile 3                | 1.271 (1.021–1.582)                 | 0.032                                 | 1.322 (1.059–1.651) | 0.014     |
| Quartile 4                | 1.045 (0.830–1.315)                 | 0.708                                 |                      |           |
| HDL-C                     |                                     |                                       |                      |           |
| Quartile 1                | Reference                           | Reference                             | 0.772 (0.600–0.993) | 0.044     |
| Quartile 2                | 0.861 (0.706–1.051)                 | 0.141                                 | 1.054 (0.860–1.291) | 0.614     |
| Quartile 3                | 0.568 (0.452–0.794)                 | <0.001                                | 0.895 (0.712–1.126) | 0.345     |
| Quartile 4                | 0.493 (0.390–0.623)                 | <0.001                                | 0.722 (0.600–0.993) | 0.044     |
| LDL-C                     |                                     |                                       |                      |           |
| Quartile 1                | Reference                           | Reference                             | 1.256 (0.997–1.583) | 0.054     |
| Quartile 2                | 1.153 (0.913–1.456)                 | 0.233                                 | 1.127 (0.891–1.426) | 0.317     |
| Quartile 3                | 1.424 (1.137–1.782)                 | 0.002                                 | 1.390 (1.108–1.743) | 0.004     |
| Quartile 4                | 1.307 (1.041–1.642)                 | 0.021                                 |                      |           |
| Chol/HDL-C ratio          |                                     |                                       |                      |           |
| Quartile 1                | Reference                           | Reference                             | 1.403 (1.097–1.793) | 0.007     |
| Quartile 2                | 1.223 (0.948–1.578)                 | 0.122                                 | 1.075 (0.832–1.391) | 0.579     |
| Quartile 3                | 1.755 (1.383–2.228)                 | <0.001                                | 1.381 (1.082–1.763) | 0.010     |
| Quartile 4                | 2.044 (1.619–2.581)                 | <0.001                                |                      |           |

Values expressed as odds ratio and 95% confidence interval (CI). Adjusted for age, sex, smoking and alcohol history, hypertension, fasting glucose, albumin and eGFR (significant variables of Table 3). The cutoff values of quartiles were ≤66, 67–93, 94–136 and >137 mg/dL of triglyceride; ≤171, 172–193,194–217 and >218 mg/dL of total cholesterol; ≤45, 46–63, 54–62 and >63 mg/dL of LDL-C; ≤100, 101–120, 121–141 and >142 mg/dL of LDL-C; and ≤3.02, 3.02–3.63, 3.64–4.38 and >4.39 of Chol/HDL-C ratio. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Chol/HDL-C, the ratio of total cholesterol to HDL-C.

Figure 3A–E illustrates the adjusted curves of incident KSD among the quartiles of lipid profile.

**Figure 3.** The adjusted curves of incident kidney stone disease among the quartiles of triglyceride (A), total cholesterol (B), HDL-C (C), LDL-C (D), and Chol/HDL-C (E). HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Chol/HDL-C, the ratio of total cholesterol to HDL-C. Dashed lines mean odds ratio. Solid lines mean 95% confidence interval.
4. Discussion

In this longitudinal study of 27,002 participants from the TWB, we investigated the association between lipid profile with baseline and incident KSD. We found that hypertriglyceridemia, high Chol/HDL-C, and low HDL-C were associated with baseline and incident KSD.

Our results showed that the participants with hypertriglyceridemia (67–93 mg/dL) had a 1.463-fold higher risk of incident KSD, and that low HDL-C (>63 mg/dL) protected against incident KSD formation. Most of the recent studies demonstrating an association between KSD and dyslipidemia have been cross-sectional analyses [5–7,9,10,27,33,34] and case-control studies [11,15,35]. Three retrospective cohort studies followed the patients for more than 5 years and found that those with dyslipidemia were at a greater risk of KSD [13,14] and recurrent KSD [12]. In addition, one prospective cohort study followed the patients for 7 years and found that hypertriglyceridemia increased the risk of developing KSD [8]. Our findings are consistent with recent studies that the subjects with stone formation had higher serum triglyceride and lower serum HDL-C levels compared to those without stone formation [11,15,27,29]. On the other hand, lower serum LDL-C and total cholesterol levels have been reported in patients with stones compared to those without stones [11,15,29]. Our results are also similar to cohort studies exploring the risk of incident KSD, which have also reported associations between hypertriglyceridemia [8] and low HDL cholesterol [13] with a higher risk of urolithiasis. Both low HDL cholesterol and hypertriglyceridemia are metabolic syndrome components, and insulin resistance, obesity, and hypertension frequently coexist with these dyslipidemic conditions. Several studies have shown an association between the chronic oxidative stress and inflammation which occur in patients with metabolic syndrome, including the expression of inflammatory molecules and the early processes of kidney stone formation [36–38]. It is evident that lifestyle habits influence metabolic syndrome, and they have also been associated with renal stone formation. Naya et al. found that arachidonic acid in food was associated with urinary oxalate excretion [39]. Meschi et al. summarized the relevant evidence and proposed that a lower fat intake could reduce the risk of KSD [40].

Some studies have reported findings inconsistent with our study. For example, two cross-sectional analyses did not find an association between KSD and lipid profiles [5,7]. There are several possible explanations for this discrepancy. First, the study populations were different. Dyslipidemia may have different impacts in different ethnicities due to differences in genetic background, geographic environment, and lifestyle factors. Second, the sample sizes were different. The two aforementioned studies included 220 and 839 nephrolithiasis patients, respectively, compared to 1813 patients with KSD in the present study. This may have limited the power to detect the possible risk factors for dyslipidemia.

Torricelli et al. reported that serum lipid profiles also influenced urine metabolic profiles and stone composition. They reported that patients with low HDL cholesterol or hypertriglyceridemia had higher urinary sodium, oxalate, and uric acid excretion and lower pH [41]. Other studies have also reported similar urine findings in patients with dyslipidemia [6,12]. Liu et al. demonstrated that statin therapy could alter the urine composition in patients with KSD, with an increase in pH and citrate level, and decrease in uric acid level [42]. The abnormal urine biochemistry in patients with dyslipidemia could partially be explained by the hypothesis that insufficient HDL may compromise the HDL-related anti-inflammatory reduction in insulin resistance [13,43]. On the other hand, Bobulescu et al. found that diabetic fatty rats with high renal triglyceride content had lower urinary pH, urinary ammonium, and brush border membrane Na+/H+ exchanger-3 (NHE3), which is a major mediator of ammonium excretion. They also incubated long-chain fatty acids with kidney cells, and their results showed an association between the accumulation of intracellular lipids with a dose-dependent decrease in NHE3 activity [44]. These results suggest that decreased renal ammonium secretion could be the consequence of renal steatosis. Another plausible explanation for the association between dyslipidemia
and KSD was implied in a review article by Stoller et al. [45]. They reported that a change in blood flow from laminar to turbulent at the papillary tip in the vasa recta may increase the risk of vascular injury and also that the cholesterol content in kidney stones may be caused by free cholesterol leaking from plasma in the fenestrated ascending vasa recta. This atherosclerotic-like plaque may then lead to vessel wall calcification and provide a nidus for the formation of calculi [45].

In this study, we also found that the participants with an elevated Chol/HDL-C ratio (>3.64) had a 1.381-fold increased risk off incident KSD. Dyslipidemia is highly associated with cardiovascular diseases, and many studies have examined the power of the various lipoproteins in predicting cardiovascular risk. Compared to using LDL-C alone to evaluate cardiovascular risk, which may underestimate the impact of very LDL-C, the Chol/HDL-C ratio has been shown to be a better predictor of cardiovascular risk [46–48]. An association between insulin resistance and a high Chol/HDL-C ratio has also been reported [46]. These findings suggest that atherosclerotic diseases may not be caused solely by a single lipoprotein, but instead by a balance between atheroprotective and atherogenic lipoproteins. Cupisti et al. investigated insulin resistance and urine composition in patients with calcium nephrolithiasis and found an association between higher insulin resistance and lower excretion of urinary citrate [49]. Moreover, Eisner et al. reported that stone formers with type 2 DM had lower urine pH and higher levels of urinary oxalate excretion than those without DM [50]. Urinary acidification has been reported to be a risk factor for uric acid stones due to low urate solubility in conditions of low urinary pH [51]. Abate et al. suggested that the mechanism underlying insulin resistance-induced KSD is probably related to induced defects in renal ammoniagenesis and increased renal citrate reabsorption [51].

To the best of our knowledge, this is the first longitudinal study to investigate associations among lipid profiles and incident KSD in Taiwan. The strengths of this study include the inclusion of a large number of participants with a long follow-up period. However, there were also several limitations. First, data on medications which may have affected dyslipidemia and KSD were not available. Second, data on the presence of KSD were obtained from self-reported questionnaires, and KSD was not verified radiographically. However, this method has been used in previous studies [6,52], and Wu and colleagues reported moderate agreement between claims record data and self-reported renal diseases in Taiwan [53]. Third, data on daily fluid intake and diet were also not available, as they fluctuate making them difficult to measure in detail. In addition, detailed data of the type of stones were also lacking. However, in Taiwan, calcium oxalate is the most common type of kidney stone, followed by calcium phosphate and uric acid, and magnesium ammonium phosphate stones are seldom found [54]. Finally, as all the participants were of Chinese ethnicity, the generalizability of our results may be limited.

5. Conclusions

In conclusion, our results demonstrated that hypertriglyceridemia, low HDL-C, and high Chol/HDL-C were associated with a higher risk of developing kidney stones. Our findings may imply that the optimal management of dyslipidemia can lower the risk of developing kidney stones.

Author Contributions: Conceptualization, J.-A.H., C.-H.L., J.-H.G., D.-W.W. and S.-C.C.; Data curation, C.-H.L., J.-H.G. and S.-C.C.; Formal analysis, J.-H.G. and S.-C.C.; Funding acquisition, S.-C.C.; Writing—original draft, J.-A.H., C.-H.L. and S.-C.C.; Writing—review & editing, S.-C.C.; Supervision, S.-C.C. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported partially by the Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan and by Kaohsiung Medical University Research Center Grant (KMU-TC109A01-1 and KMUTC111IFSP01).
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUHIRB-E(1)-20210058 and 2021/4/8 approval).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data underlying this study is from the Taiwan Biobank. Due to restrictions placed on the data by the Personal Information Protection Act of Taiwan, the minimal data set cannot be made publicly available. Data may be available upon request to interested researchers. Please send data requests to: Szu-Chia Chen. Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Raheem, O.A.; Khandwala, Y.S.; Sur, R.L.; Ghani, K.R.; Derstedt, J.D. Burden of Urolithiasis: Trends in Prevalence, Treatments, and Costs. *Eur. Urol. Focus* 2017, 3, 18–26. [CrossRef] [PubMed]
2. Huang, W.Y.; Chen, Y.F.; Carter, S.; Chang, H.C.; Lan, C.F.; Huang, K.H. Epidemiology of upper urinary tract stone disease in a Taiwanese population: A nationwide, population based study. *J. Urol.* 2013, 189, 2158–2163. [CrossRef] [PubMed]
3. Moe, O.W. Kidney stones: Pathophysiology and medical management. *Lancet* 2006, 367, 333–344. [CrossRef]
4. Alelign, T.; Petrovs. Kidney Stone Disease: An Update on Current Concepts. *Adv. Urol.* 2018, 2018, 3068365. [CrossRef] [PubMed]
5. Jeong, I.G.; Kang, T.; Bang, J.K.; Park, J.; Kim, W.; Hwang, S.S.; Kim, H.K.; Park, H.K. Association between metabolic syndrome and the presence of kidney stones in a screened population. *Am. J. Kidney Dis.* 2011, 58, 383–388. [CrossRef]
6. Kohjimoto, Y.; Sasaki, Y.; Iguchi, M.; Matsumura, N.; Inagaki, T.; Hara, I. Association of metabolic syndrome traits and severity of kidney stones: Results from a nationwide survey on urolithiasis in Japan. *Am. J. Kidney Dis.* 2013, 61, 923–929. [CrossRef]
7. Rendina, D.; Mossetti, G.; De Filippo, G.; Benvenuto, D.; Vivona, C.L.; Imbroinise, A.; Zampa, G.; Ricchio, S.; Strazzullo, P. Association between metabolic syndrome and nephrolithiasis in an inpatient population in southern Italy: Role of gender, hypertension and abdominal obesity. *Nephrol. Dial. Transplant.* 2009, 24, 900–906. [CrossRef]
8. Chang, I.H.; Lee, Y.T.; Lee, D.M.; Kim, T.H.; Myung, S.C.; Kim, Y.S.; Ahn, S.H. Metabolic syndrome, urine pH, and time-dependent risk of nephrolithiasis in Korean men without hypertension and diabetes. *Urology* 2011, 78, 753–758. [CrossRef]
9. Jung, H.S.; Chang, I.H.; Moon, Y.T.; Kim, T.H.; Myung, S.C.; Kim, Y.S.; Lee, J.Y. Possible Relationship between Metabolic Syndrome Traits and Nephrolithiasis: Incidence for 15 Years According to Gender. *Korean J. Urol.* 2011, 52, 548–553. [CrossRef]
10. Lee, Y.C.; Huang, S.P.; Juan, Y.S.; Huang, T.Y.; Liu, C.C. Impact of metabolic syndrome and its components on kidney stone in aging Taiwanese males. *Aging Male* 2016, 19, 197–201. [CrossRef]
11. Kang, H.W.; Lee, S.K.; Kim, W.T.; Kim, Y.J.; Yun, S.J.; Lee, S.C.; Kim, W.J. Hypertriglyceridemia and low high-density lipoprotein cholesterolemia are associated with increased hazard for urolithiasis. *J. Endourol.* 2014, 28, 1001–1005. [CrossRef] [PubMed]
12. Kang, H.W.; Seo, S.P.; Kim, W.T.; Kim, Y.J.; Yun, S.J.; Lee, S.C.; Kim, W.J. Hypertriglyceridemia is associated with increased risk for stone recurrence in patients with urolithiasis. *Urology* 2014, 84, 766–771. [CrossRef] [PubMed]
13. Masterson, J.H.; Woo, J.R.; Chang, D.C.; Chi, T.; L’Esperance, J.O.; Stoller, M.L.; Sur, R.L. Dyslipidemia is associated with an increased risk of nephrolithiasis. *Urolithiasis* 2015, 43, 49–53. [CrossRef]
14. Rezaee, M.E.; Ward, C.E.; Pollock, M.; Shetty, S.D. Association between multiple chronic conditions and urolithiasis. *Int. Urol. Nephrol.* 2017, 49, 1361–1367. [CrossRef] [PubMed]
15. Ding, Q.; Ouyang, J.; Fan, B.; Cao, C.; Fan, Z.; Ding, L.; Li, F.; Tu, W.; Jin, X.; Wang, J.; et al. Association between Dyslipidemia and Nephrolithiasis Risk in a Chinese Population. *Urol. Int.* 2019, 103, 156–165. [CrossRef] [PubMed]
16. Kabeya, Y.; Kato, K.; Tomita, M.; Katsuki, T.; Oikawa, Y.; Shimada, A.; Atsumi, Y. Associations of insulin resistance and glycemic control with the risk of kidney stones. *Intern. Med.* 2012, 51, 699–705. [CrossRef] [PubMed]
17. Weinberg, A.E.; Patel, C.J.; Chertow, G.M.; Leppert, J.T. Diabetic severity and risk of kidney stone disease. *Eur. Urol.* 2014, 65, 242–247. [CrossRef]
18. Eisner, B.H.; Porten, S.P.; Bechis, S.K.; Stoller, M.L. Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis. *J. Urol.* 2010, 183, 576–579. [CrossRef]
19. Kim, Y.J.; Park, M.S.; Kim, W.T.; Yun, S.J.; Kim, W.J.; Lee, S.C. Hypertension influences recurrent stone formation in nonobese stone formers. *Urology* 2011, 77, 1059–1063. [CrossRef]
20. Whitehurst, L.; Jones, P.; Somani, B.K. Mortality from kidney stone disease (KSD) as reported in the literature over the last two decades: A systematic review. *World J. Urol.* 2019, 37, 759–776. [CrossRef]
21. Keddis, M.T.; Rule, A.D. Nephrolithiasis and loss of kidney function. *Curr. Opin. Nephrol. Hypertens.* 2013, 22, 390–396. [CrossRef] [PubMed]
22. Cupisti, A. Update on nephrolithiasis: Beyond symptomatic urinary tract obstruction. *J. Nephrol.* 2011, 24 (Suppl. S18), S25–S29. [CrossRef] [PubMed]
23. Ford, E.S.; Giles, W.H.; Dietz, W.H.; Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287, 356–365. [CrossRef] [PubMed]
24. Karr, S. Epidemiology and management of hyperlipidemia. Am. J. Manag. Care 2017, 23, S139–S148.
25. Stamler, J.; Daviğlus, M.L.; Garside, D.B.; Dyer, A.R.; Greenland, P.; Neaton, J.D. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000, 284, 311–318. [CrossRef]
26. Yaghi, S.; Elkind, M.S. Lipids and Cerebrovascular Disease: Research and Practice. Stroke 2015, 46, 3322–3328. [CrossRef]
27. Kim, Y.J.; Kim, C.H.; Sung, E.J.; Kim, S.R.; Shin, H.C.; Jung, W.J. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism 2013, 62, 808–813. [CrossRef]
28. Sur, R.L.; Masterson, J.H.; Palazzi, K.L.; I’Esperance, J.O.; Auge, B.K.; Chang, D.C.; Stoller, M.I. Impact of statins on nephrolithiasis in hyperlipidemic patients: A 10-year review of an equal access health care system. Clin. Nephrol. 2013, 79, 351–355. [CrossRef]
29. Cohen, A.J.; Adamsky, M.; Palazzi, K.L.; L’Esperance, J.O.; Auge, B.K.; Chang, D.C.; Wang, C.H.; Park, S. Impact of Statin Intake on Kidney Stone Formation. Urology 2019, 124, 57–61. [CrossRef]
30. Cohen, A.J.; Adamsmy, M.; Palazzi, K.L.; L’Esperance, J.O.; Auge, B.K.; Chang, D.C.; Wang, C.H.; Park, S. Impact of Statin Intake on Kidney Stone Formation. Urology 2019, 124, 57–61. [CrossRef]
31. Chen, C.H.; Yang, J.H.; Chiang, C.W.K.; Hsiung, C.N.; Wu, P.E.; Chang, L.C.; Chu, H.W.; Chang, J.; Song, I.W.; Yang, S.L.; et al. Population structure of Han Chinese in the modern Taiwanese population based on 10,000 participants in the Taiwan Biobank project. Hum. Mol. Genet. 2016, 25, 5321–5331. [CrossRef]
32. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D.A. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130, 461–470. [CrossRef] [PubMed]
33. Ando, R.; Nogaya, T.; Suzuki, S.; Takahashi, H.; Kawai, M.; Okada, A.; Yasui, T.; Kubota, Y.; Umemoto, Y.; Tozawa, K.; et al. Kidney stone formation is positively associated with conventional risk factors for coronary heart disease in Japanese men. J. Urol. 2013, 189, 1340–1346. [CrossRef]
34. Liu, Y.T.; Yang, P.Y.; Yang, Y.W.; Sun, H.Y.; Lin, L.C. The association of nephrolithiasis with metabolic syndrome and its components: A cross-sectional analysis. Ther. Clin. Risk Manag. 2017, 13, 41–48. [CrossRef] [PubMed]
35. Inci, M.; Demirats, A.; Sarli, B.; Akinsal, E.; Baydilli, N. Association between body mass index, lipid profiles, and types of urinary stones. Ren. Fail. 2012, 34, 1140–1143. [CrossRef]
36. Khan, S.R. Crystal-induced inflammation of the kidneys: Results from human studies, animal models, and tissue-culture studies. Clin. Exp. Nephrol. 2004, 8, 75–88. [CrossRef] [PubMed]
37. Besiroglu, H.; Otuncetemur, A.; Ozbek, E. The metabolic syndrome and urolithiasis: A systematic review and meta-analysis. Ren. Fail. 2015, 37, 1–6. [CrossRef]
38. Ozbek, E. Induction of oxidative stress in kidney. Int. J. Nephrol. 2012, 2012, 465897. [CrossRef]
39. Naya, Y.; Itou, H.; Masai, M.; Yamaguchi, K. Association of dietary fatty acids with urinary oxalate excretion in calcium oxalate stone-formers in their fourth decade. BJU Int. 2002, 89, 842–846. [CrossRef]
40. Meschi, T.; Nourvenne, A.; Borghi, L. Lifestyle recommendations to reduce the risk of kidney stones. Urol. Clin. N. Am. 2011, 38, 313–320. [CrossRef]
41. Torricelli, F.C.; De, S.K.; Gebrejohannes, S.; Li, I.; Sarkissian, C.; Monga, M. Dyslipidemia and kidney stone risk. J. Urol. 2014, 191, 667–672. [CrossRef] [PubMed]
42. Liu, C.J.; Huang, H.S. Statins significantly alter urinary stone-related urine biochemistry in calcium oxalate stone patients with dyslipidemia. Int. J. Nephrol. 2020, 27, 839–844. [CrossRef] [PubMed]
43. Hoofnagle, A.N.; Vaisar, T.; Mitra, P.; Chait, A. HDL lipids and insulin resistance. Curr. Diab. Rep. 2010, 10, 78–86. [CrossRef] [PubMed]
44. Bobulescu, I.A.; Dubree, M.; Zhang, J.; McLeroy, P.; Moe, O.W. Effect of renal lipid accumulation on proximal tubule Na\(^{+}\)/H\(^{+}\) exchange and ammonium secretion. Am. J. Physiol. Ren. Physiol. 2008, 294, F1315–F1322. [CrossRef] [PubMed]
45. Stoller, M.I.; Meng, M.V.; Abrahams, H.M.; Kane, J.P. The primary stone event: A new hypothesis involving a vascular etiology. J. Urol. 2004, 171, 1920–1924. [CrossRef]
46. Lemieux, I.; Lamarche, B.; Couillard, C.; Pascot, A.; Cantin, B.; Bergeron, J.; Dagenais, G.R.; Despres, J.P. Total cholesterol/HDL cholesterol ratio vs. LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: The Quebec Cardiovascular Study. Arch. Intern. Med. 2001, 161, 2685–2692. [CrossRef]
47. Arsenault, B.J.; Boekholdt, S.M.; Kastelein, J.J. Lipid parameters for measuring risk of cardiovascular disease. Nat. Rev. Cardiol. 2011, 8, 197–206. [CrossRef]
48. Ingeleissen, E.; Schaefer, E.J.; Contois, J.H.; McNamara, J.R.; Sullivan, L.; Keyses, M.J.; Pencina, M.J.; Schoonmaker, C.; Wilson, P.W.; D’Agostino, R.B.; et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298, 776–785. [CrossRef]
49. Cupisti, A.; Meola, M.; D’Alessandro, C.; Bernabini, G.; Pascuali, E.; Carpi, A.; Barsotti, G. Insulin resistance and low urinary citrate excretion in calcium stone formers. Biomed. Pharmacother. 2007, 61, 86–90. [CrossRef]
50. Eisner, B.H.; Porten, S.P.; Bechis, S.K.; Stoller, M.I. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J. Urol. 2010, 183, 2244–2248. [CrossRef]
51. Abate, N.; Chandalia, M.; Cabo-Chan, A.V., Jr.; Moe, O.W.; Sakhaee, K. The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. *Kidney Int.* **2004**, *65*, 386–392. [CrossRef] [PubMed]

52. West, B.; Luke, A.; Durazo-Arvizu, R.A.; Cao, G.; Shoham, D.; Kramer, H. Metabolic syndrome and self-reported history of kidney stones: The National Health and Nutrition Examination Survey (NHANES III) 1988-1994. *Am. J. Kidney Dis.* **2008**, *51*, 741–747. [CrossRef] [PubMed]

53. Wu, C.S.; Lai, M.S.; Gau, S.S.; Wang, S.C.; Tsai, H.J. Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. *PLoS ONE* **2014**, *9*, e112257. [CrossRef] [PubMed]

54. Chou, Y.H.; Li, C.C.; Wu, W.J.; Juan, Y.S.; Huang, S.P.; Lee, Y.C.; Liu, C.C.; Li, W.M.; Huang, C.H.; Chang, A.W. Urinary stone analysis of 1,000 patients in southern Taiwan. *Kaohsiung J. Med. Sci.* **2007**, *23*, 63–66. [CrossRef]